New drug cocktail tested to shrink tough pancreatic tumors before surgery
NCT ID NCT07469956
Summary
This study is testing a combination of three types of drugs—a targeted therapy, an immunotherapy, and a chemotherapy regimen—given to patients before surgery for high-risk or borderline operable pancreatic cancer. The goal is to see if this approach can shrink tumors more effectively, make surgery more successful, and ultimately help patients live longer without their cancer returning. Researchers will enroll about 30 patients to evaluate both the effectiveness and safety of this intensive treatment strategy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER RESECTABLE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun Yat-sen University Cancer Center
Guangzhou, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.